Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone

Completed · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

The purpose of this study is to assess the safety and effectiveness of KRP-104 on glycemic control in patients with type 2 diabetes inadequately controlled on metformin alone.

Key facts

Study ID

NCT00995345

Run by

ActivX Biosciences, Inc.

People needed

403

Starts

2009-10-01

Expected to finish

2011-01-01

Last updated by the study team

2014-06-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients meeting the following criteria at the screening visit (Visit 1) will be eligible to participate in the trial:
• Signed written informed consent;
• Males and females 18 to 75 years of age, inclusive;
• Females of childbearing potential must agree to use 2 adequate forms of barrier method contraception (eg, latex condom AND intrauterine device or a diaphragm) to avoid pregnancy while in the study;
• On a stable dose (Greater than or equal to 10 weeks at the same dose) of metformin monotherapy (Less than or equal to 1500 mg/day or maximum tolerated dose), have an HbA1c greater than or equal to 7.0% and less than or equal to 10.5%; or
• On metformin (less than or equal to 1500 mg/day) and 1 other antidiabetic agent (excluding TZD, insulin, or incretin therapies [DPP-4 inhibitors and GLP-1 analogues]) and have an HbA1c greater than or equal to 6.8% and less than or equal to 10.0%; or
• Not on antidiabetic therapy (for at least 3 months prior to Visit 1) or have not been on a stable dose of metformin monotherapy for 10 weeks and have an HbA1c greater than or equal to 8.0% and less than or equal to 11.0%.

You may not qualify if…

• History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent hypoglycemia;
• History or presence of alcoholism or drug abuse within the 2 years prior to dosing;
• Typical consumption of greater than or equal to 10 drinks of alcohol weekly;
• Presence of any of the following conditions:
• Significant renal impairment (glomerular filtration rate less than 60 mL/min);
• Diabetic gastroparesis;
• Active liver disease (other than asymptomatic nonalcoholic fatty liver disease), cirrhosis, or symptomatic gallbladder disease;
• Fasting plasma glucose/blood glucose greater than 240 mg/dL (13.3 mmol/L) at Visit 3 (Week -2) (1 laboratory retest permitted);
• Body mass index less than or equal to 20 kg/m2 and greater than or equal to 48 kg/m2;
• Systolic blood pressure <100 mmHg or >160 mmHg and diastolic blood pressure <50 mmHg or >100 mmHg at Visit 3 (Note: medication to control blood pressure is allowed and should be optimized and stabilized prior to Visit 3);
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 X the upper limit of normal (ULN) (1 laboratory retest permitted);
• Creatine phosphokinase (CPK) greater than 2 X the ULN (if not explained by muscular trauma or exercise) (1 laboratory retest permitted);
• Serum creatinine >1.5 mg/dL for males (132.6 μmol/L) and 1.4 mg/dL for females (123.8 μmol/L);
• Fasting triglycerides (TG) >600 mg/dL (6.78 mmol/L) at Visit 3 (Week -2) (Note: diet/exercise and lipid-lowering medication to control elevated TG is allowed; medications should be optimized and stabilized prior to Visit 3);
• Treatment with pioglitazone or rosiglitazone within the previous 10 weeks (Visit 1); treatment with incretin therapy (DPP-4 inhibitors or GLP-1 analogues) within the previous 4 weeks (Visit 1);
• Treatment with any type of insulin (ie, injected or inhaled) within the previous 3 months;
• Must meet other laboratory and Medical History clinical criteria. Please contact recruitment center for referrals

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Phoenix, Arizona, United States
• Study site — Los Angeles, California, United States
• Study site — Valley Village, California, United States
• Study site — Honolulu, Hawaii, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Delaware, Ohio, United States
• Study site — Marion, Ohio, United States
• Study site — Beaver, Pennsylvania, United States
• Study site — Jenkintown, Pennsylvania, United States
• Study site — Greer, South Carolina, United States
• Study site — Austin, Texas, United States
• Study site — Houston, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Sandy City, Utah, United States
• Study site — West Jordan, Utah, United States
• Study site — Buenos Aires, Argentina
• Study site — Córdoba, Argentina
• Study site — Loma Hermos Buenos Aires, Argentina
• Study site — Chrudim III, Czechia
• Study site — Holešov, Czechia
• Study site — Mělník, Czechia
• Study site — Ostrava, Czechia
• Study site — Prague, Czechia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.